MetaVia Inc. (MTVA)
$1.43-1.38%Close
SELLCRISIS · day 10
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $3M
- Beta
- 0.96
- P/E (TTM)
- -0.35
- Short % float
- 11.96%
- Days to cover
- 2.0
- SI change
- -36.0%
- 1W
- -3.38%
- 1M
- -11.73%
- vs SPY 1W
- -3.24%
- vs SPY 1M
- -14.23%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 18
- VALUE
- 18
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-125.8%
REV YoY-
ROE-209.7%
EPS YoY-
ROA-108.9%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.35
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.24
P/FCF-
EV/EBITDA0.21
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E2.59
ALTMAN Z-
CURR RATIO2.06
ND/EBITDA-
BETA0.96
Company news
FAQ
- What is LOPJLB’s current signal on MTVA?
- LOPJLB’s latest quantitative signal on MetaVia Inc. (MTVA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MTVA in?
- MetaVia Inc. (MTVA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does MetaVia Inc. (MTVA) do?
- Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associat…